BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24946721)

  • 1. Expression of TGFβ-1 and EHD1 correlated with survival of non-small cell lung cancer.
    Gao Y; Wang Y; Sun L; Meng Q; Cai L; Dong X
    Tumour Biol; 2014 Sep; 35(9):9371-80. PubMed ID: 24946721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of Eps15 homology domain 1 is negatively correlated with disease-free survival and overall survival of osteosarcoma patients.
    Yu H; Qu G; Wang Y; Mai W; Bao JJ; Song C; Yao M
    J Orthop Surg Res; 2019 Apr; 14(1):103. PubMed ID: 30975166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased EHD1 in non-small cell lung cancer predicts poor survival.
    Lu H; Meng Q; Wen Y; Hu J; Zhao Y; Cai L
    Thorac Cancer; 2013 Nov; 4(4):422-432. PubMed ID: 28920217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGF-β1 precursor and CD8 are potential prognostic and predictive markers in operated breast cancer.
    Yu HM; Yang JL; Jiao SC; Wang JD; Li Y
    J Huazhong Univ Sci Technolog Med Sci; 2014 Feb; 34(1):51-58. PubMed ID: 24496679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Expression of Eps15 Homology Domain 1 is Associated with Poor Prognosis in Resected Small Cell Lung Cancer.
    Meng Q; Sun W; Li M; Zhao Y; Chen X; Sun L; Cai L
    J Cancer; 2015; 6(10):990-5. PubMed ID: 26366212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.
    Mascaux C; Wynes MW; Kato Y; Tran C; Asuncion BR; Zhao JM; Gustavson M; Ranger-Moore J; Gaire F; Matsubayashi J; Nagao T; Yoshida K; Ohira T; Ikeda N; Hirsch FR
    Clin Cancer Res; 2011 Dec; 17(24):7796-807. PubMed ID: 21994417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
    Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
    Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
    Cappuzzo F; Hirsch FR; Rossi E; Bartolini S; Ceresoli GL; Bemis L; Haney J; Witta S; Danenberg K; Domenichini I; Ludovini V; Magrini E; Gregorc V; Doglioni C; Sidoni A; Tonato M; Franklin WA; Crino L; Bunn PA; Varella-Garcia M
    J Natl Cancer Inst; 2005 May; 97(9):643-55. PubMed ID: 15870435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers.
    Wang X; Yin H; Zhang H; Hu J; Lu H; Li C; Cao M; Yan S; Cai L
    Cell Death Dis; 2018 Apr; 9(4):418. PubMed ID: 29549343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients.
    Pajares MJ; Agorreta J; Salvo E; Behrens C; Wistuba II; Montuenga LM; Pio R; Rouzaut A
    Br J Cancer; 2014 Mar; 110(6):1545-51. PubMed ID: 24481402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
    Spigel DR; Ervin TJ; Ramlau RA; Daniel DB; Goldschmidt JH; Blumenschein GR; Krzakowski MJ; Robinet G; Godbert B; Barlesi F; Govindan R; Patel T; Orlov SV; Wertheim MS; Yu W; Zha J; Yauch RL; Patel PH; Phan SC; Peterson AC
    J Clin Oncol; 2013 Nov; 31(32):4105-14. PubMed ID: 24101053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian Eps15 homology domain 1 potentiates angiogenesis of non-small cell lung cancer by regulating β2AR signaling.
    Wang T; Xing Y; Meng Q; Lu H; Liu W; Yan S; Song Y; Xu X; Huang J; Cui Y; Jia D; Cai L
    J Exp Clin Cancer Res; 2019 Apr; 38(1):174. PubMed ID: 31023336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.
    Bell EH; Chakraborty AR; Mo X; Liu Z; Shilo K; Kirste S; Stegmaier P; McNulty M; Karachaliou N; Rosell R; Bepler G; Carbone DP; Chakravarti A
    Clin Cancer Res; 2016 May; 22(10):2396-404. PubMed ID: 26671993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.
    Mak RH; Doran E; Muzikansky A; Kang J; Neal JW; Baldini EH; Choi NC; Willers H; Jackman DM; Sequist LV
    Oncologist; 2011; 16(6):886-95. PubMed ID: 21632451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive expression of pro-opiomelanocortin (POMC) is a novel independent poor prognostic marker in surgically resected non-small cell lung cancer.
    Hao L; Zhao X; Zhang B; Li C; Wang C
    Tumour Biol; 2015 Mar; 36(3):1811-7. PubMed ID: 25377161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC.
    Zhang T; Rong N; Chen J; Zou C; Jing H; Zhu X; Zhang W
    PLoS One; 2013; 8(11):e79162. PubMed ID: 24223900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors after complete resection of pN2 non-small cell lung cancer.
    Sonobe M; Date H; Wada H; Okubo K; Hamakawa H; Teramukai S; Matsumura A; Nakagawa T; Sumitomo S; Miyamoto Y; Okumura N; Takeo S; Kawakami K; Aoki M; Kosaka S;
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):788-95. PubMed ID: 23810113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of clinical T4 stage superior sulcus non-small cell lung cancer: a propensity-matched analysis of the surveillance, epidemiology, and end results database.
    Wen J; Liu D; Chen D; Chen J; Xu X; Chen C; Zhang F; Duan S; Zhu R; Fan M; Chen Y
    Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30647107
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib.
    Winther-Larsen A; Fledelius J; Sorensen BS; Meldgaard P
    Lung Cancer; 2016 Apr; 94():81-7. PubMed ID: 26973211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.